X0508 4 2024-04-25 0001636282 Spyre Therapeutics, Inc. SYRE 0001802528 Fairmount Funds Management LLC 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 true false false false 0001769651 Fairmount Healthcare Fund II L.P. 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 true false false false 0001830177 Kiselak Tomas 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 true false false false 0001663607 Harwin Peter Evan 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 true false false false false Common Stock 2024-04-25 4 M false 3639680 0 A 4018101 I By Fairmount Healthcare Fund II L.P. Common Stock 406038 I By Tomas Kiselak Common Stock 406038 I By Peter Harwin Series A Preferred Stock 2024-04-25 4 M false 90992 0 D Common Stock 3639680 346045 I By Fairmount Healthcare Fund II L.P. Pursuant to an Exchange Agreement between Fairmount Healthcare Fund II L.P. ("Fund II") and the Issuer dated as of April 23, 2024, Fund II exchanged 90,992 shares of Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") for 3,639,680 shares of Common Stock, effective on April 25, 2024. Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fund II. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Each share of Series A Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Reporting Persons may each be deemed a director by deputization of Issuer by virtue of the fact that each of Peter Harwin and Tomas Kiselak serve on the board of directors of Issuer and are also each a Managing Member of Fairmount Funds Management LLC. /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC 2024-04-25 /s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Fund II L.P. 2024-04-25 /s/ Tomas Kiselak 2024-04-25 /s/ Peter Harwin 2024-04-25